August 20, 2024
1 min read
Save
Visiox Pharmaceuticals merges with Ocuvex Therapeutics
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Visiox Pharmaceuticals has entered into a definitive merger agreement with Ocuvex Therapeutics, according to a press release.
The company will operate under the Ocuvex name and include Visiox’s products, including Omlonti (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine 0.35%) and SDN-037 (difluprednate 0.04%).
“The combination of Visiox and Ocuvex makes for a perfect match,” Ryan S. Bleeks, CEO of Visiox, said in the release. “We have reached significant milestones with our products, and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care.”
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.